David AuCoin cofounded DxDiscovery and currently serves as the company’s Chief Executive Officer. Dr. AuCoin is also an Associate Professor of Microbiology at the University of Nevada School of Medicine. He has nearly 15 years experience in the study of viral, bacterial and fungal immunology and pathogenesis. Currently, his research is focused on developing diagnostics and therapeutics for microbial infections. He developed a strategy termed “In vivo Microbial Antigen Discovery” (InMAD) that has allowed for the identification of secreted/shed diagnostic antigens. Dr. AuCoin has three active research grants through the National Institutes of Health. Two additional grants were recently secured through the Department of Homeland Security and the Naval Research Laboratory. Dr. AuCoin received his B.S. from the University of Massachusetts at Amherst followed by his M.S. and Ph.D. in Cell and Molecular Biology from the University of Nevada. Dr. AuCoin completed a postdoctoral fellowship at Stanford University 2005.